IBRANCE is a prescription medicine used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that has spread to other parts of the body (metastatic) in combination with:
- an aromatase inhibitor as the first hormonal based therapy in women who have gone through menopause, or
- fulvestrant in women with disease progression following hormonal therapy.
Talk to your healthcare team to see if IBRANCE is right for you.
IBRANCE may cause serious side effects, including:
Low white blood cell counts (neutropenia). Low white blood cell counts are very common when taking IBRANCE and may cause serious infections that can lead to death. Your doctor should check your white blood cell counts before and during treatment.
If you develop low white blood cell counts during treatment with IBRANCE, your doctor may stop your treatment, decrease your dose, or may tell you to wait to begin your treatment cycle. Tell your doctor right away if you have signs and symptoms of low white blood cell counts or infections such as fever and chills.
For more information, see side effects.
Before you take IBRANCE, tell your doctor if you:
- have fever, chills, or any other signs or symptoms of infection.
- have liver or kidney problems.
- have any other medical conditions.
- are pregnant or plan to become pregnant; IBRANCE can harm your unborn baby.
- Females who are able to become pregnant and who take IBRANCE should use effective birth control during treatment and for at least 3 weeks after stopping IBRANCE.
- Males who are taking IBRANCE and have female partners who can become pregnant should use effective birth control during treatment with IBRANCE and for 3 months after the final dose of IBRANCE.
- are breastfeeding or plan to breastfeed; it is not known if IBRANCE passes into your breast milk. You and your doctor should decide if you will take IBRANCE or breastfeed. You should not do both.
Yes. To monitor your side effects, your healthcare team will give you a blood test to check your complete blood cell count before you start taking IBRANCE at the beginning of every cycle.
Additionally, for the first 2 treatment cycles, you'll need a complete blood cell count done on day 15 as well. Make sure to tell your healthcare team which day you start your first and second cycles, so they can schedule your day 15 appointment at the right time.
If your results indicate low white blood cell counts (neutropenia), your healthcare team may temporarily hold or adjust your dose. It's not uncommon to have doses modified throughout treatment. Be sure to follow your dosing schedule exactly as your healthcare team prescribes.
Alopecia (hair thinning or hair loss) is a common side effect of IBRANCE. The majority of women who experienced alopecia had hair thinning rather than hair loss.
Hormone receptor-positive (HR+) is a subtype of breast cancer that includes both ER+ and/or PR+ subtypes and grows in response to 2 different hormones—estrogen and/or progesterone. If your cancer grows in response to the hormone estrogen, your cancer could also be called estrogen receptor-positive (ER+). If your cancer grows in response to the hormone progesterone, it could be called progesterone receptor-positive (PR+).
Yes, the Pfizer Oncology Together Co-Pay Savings Program may help eligible, commercially insured patients save on out-of-pocket costs, and
A CDK 4/6 inhibitor is a type of treatment that works to put the brakes on cell growth and division by preventing certain proteins (called CDK 4 and CDK 6) from telling the cell that it needs to grow and divide.
IBRANCE is in a class of drugs called CDK 4/6 inhibitors that work to put the brakes on cell growth and division in both healthy and cancer cells. This helps slow the progression of cancer, but it can also cause side effects, some of which are serious. Please see the Important Safety Information to learn more.